• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

    2/1/22 9:53:02 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGI alert in real time by email
    SC 13D/A 1 sc13da.htm AMENDMENT NO. 1



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13D

    Under the Securities Exchange Act of 1934 
    (Amendment No. 1)



    ORGANIGRAM HOLDINGS INC.
    (Name of Issuer)

    Common stock, no par value
    (Title of Class of Securities)

    68620P101
    (CUSIP Number)

    John R. Whitener
    BT DE Investments Inc.
    103 Foulk Road, Suite 111
    Wilmington, DE 19803
    (302) 656-1950

    Copy to:

    Alyssa K. Caples
    Cravath, Swaine & Moore LLP
    CityPoint
    One Ropemaker Street
    London EC2Y 9HR, United Kingdom
    +44 (0) 20 7453 1000
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 12, 2022
    (Date of Event which Requires Filing of this Statement)



    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    1
    NAMES OF REPORTING PERSONS
     
     
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BT DE Investments Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF (See Item 3 of the Original Schedule 13D, as defined below)
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     58,336,392 (See Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     58,336,392 (See Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     58,336,392 (See Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
     18.8% (See Item 5)

     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     CO
     
     
     
     



    1
    NAMES OF REPORTING PERSONS
     
     
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     British American Tobacco p.l.c.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     AF (See Item 3 of the Original Schedule 13D, as defined below)
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     England and Wales
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     58,336,392 (See Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     58,336,392 (See Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     58,336,392 (See Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     18.8% (See Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     CO
     
     
     
     

                  This statement constitutes Amendment No. 1 (“Amendment No. 1”) to the Schedule 13D (the “Original Schedule 13D”) filed with the Securities and Exchange Commission (“SEC”) on March 10, 2021 relating to shares of the common stock (the “Shares”) of Organigram Holdings Inc. (the “Issuer”). This Amendment No. 1 amends the Original Schedule 13D on behalf of the undersigned to reflect a change in the percentage of the outstanding shares of common stock, no par value, of the Issuer represented by the Shares and to furnish the other information set forth herein. Except as set forth below, all Items of the Original Schedule 13D remain unchanged. Capitalized terms used but not defined in this Amendment No. 1 have the meaning assigned to them in the Original Schedule 13D.



    ITEM 2. IDENTITY AND BACKGROUND

    Paragraph (c) of Item 2 of the Original Schedule 13D is hereby amended by replacing Schedule B to the Original Schedule 13D (which was incorporated by reference therein) with Schedule B-1 hereto and which is incorporated by reference herein.

    ITEM 4. PURPOSE OF TRANSACTION

    Item 4 of the Original Schedule 13D is hereby amended to add the following at the end thereof:

    Mr. Jeyan Heper resigned from the Board effective October 31, 2021.

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

    Paragraph (a) of Item 5 of the Original Schedule 13D is hereby amended to add the following at the end thereof:
                
    As a result of an increase in the outstanding shares of common stock, no par value, of the Issuer, the Shares comprise approximately 18.8% of the outstanding shares of common stock, no par value, of the Issuer (based on the shares of common stock, no par value, of the Issuer outstanding as of December 31, 2021).
     



    SIGNATURE

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

    Date: February 1, 2022

     
    BT DE Investments Inc.
     
           

    By:
    /s/ John R. Whitener  
        Name: John R. Whitener
     
        Title: Treasurer
     
           


     
    British American Tobacco p.l.c.
     
           

    By:
    /s/ Tadeu Marroco  
        Name:
    Tadeu Marroco
     
        Title:
    Finance and Transformation Director
     
           



    SCHEDULE B-1
    BAT DIRECTORS AND OFFICERS

    The name, country of citizenship and current principal occupation or employment of each of the BAT Directors and Officers are set forth below. Unless otherwise indicated in the tables below (i) each occupation set forth opposite an individual’s name refers to a position with a BAT Entity and (ii) the business address of such individual is Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom.

    British American Tobacco p.l.c.

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Luc Jobin (Chairman)
     
    Canada
     
    Chairman of the Board of BAT and Non-Executive Director of Gildan Activewear Inc.
    Dimitri Panayotopoulos (Senior Independent Director)
     
    Greece and United Kingdom
     
    Senior Independent Director of BAT, Senior Advisor at the Boston Consulting Group, Advisory Board member of JBS USA and a Board member of IRI and North Atlantic Acquisition Corporation
    Jack Bowles (Chief Executive)
     
    France
     
    Chief Executive of BAT
    Tadeu Marroco (Finance and Transformation Director)
     
    Brazil
     
    Finance and Transformation Director of BAT
    Susan Farr (Non-Executive Director)
     
    United Kingdom
     
    Non-Executive Director of BAT, Accsys Technologies plc, Helical plc and Unlimited Group Ltd
    Karen Guerra (Non-Executive Director)
     
    United Kingdom
     
    Non-Executive Director of BAT and Amcor p.l.c
    Dr. Marion Helmes (Non-Executive Director)
     
    Germany
     
    Chairwoman of the Supervisory Board of ProSiebenSat.1 Media SE, Supervisory Board member of Siemens Healthineers AG and Heineken N.V. and Non-Executive Director of BAT
    Holly Keller Koeppel (Non-Executive Director)
     
    U.S.A.
     
    Non-Executive Director of BAT and Flutter Entertainment plc and a Director of The AES Corporation and Arch Coal Inc.
    Savio Kwan (Non-Executive Director)
     
    United Kingdom
     
    Co-Founder and CEO of A&K Consulting Co Ltd, Non-Executive Director of BAT, The Alibaba Hong Kong Entrepreneur Fund, Crossborder Innovative Ventures International Limited, GOGOX and Southern England Wines Ltd, Advisory Board and Non-Executive Director of Homaer Financial, Visiting Professor of Henley Business School, and Member of Governing Body of London Business School
    Darrell Thomas (Non-Executive Director)
     
    U.S.A.
     
    Vice President and Treasurer of Harley-Davidson, Inc., Non-Executive Director of BAT, Independent Director of Dorman Products Inc., and Board member of Sojourner Family Peace Center Inc.



    British American Tobacco (1998) Limited

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Jerome Abelman
     
    U.S.A.
     
    Director, Legal and External Affairs and General Counsel
    Hae In Kim
     
    South Korea
     
    Director, Talent, Culture and Inclusion
    Tadeu Marroco
     
    Brazil
     
    Finance and Transformation Director
    Kingsley Wheaton
     
    United Kingdom
     
    Chief Marketing Officer

    British American Tobacco (2012) Limited

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    David Booth
     
    United Kingdom
     
    Group Chief Accountant
    Anthony Cohn
     
    United Kingdom
     
    Head of Corporate Tax - UK
    Ruth Wilson
     
    United Kingdom
     
    Head of Group Corporate Governance
    Ridirectors Limited (Globe House, 1 Water Street,
    London, England, WC2R 3LA)
     
    Incorporated in the United Kingdom
     
    Corporate director (non-trading company)

    British American Tobacco (2009) Limited

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    David Booth
     
    United Kingdom
     
    Group Chief Accountant
    Anthony Cohn
     
    United Kingdom
     
    Head of Corporate Tax - UK
    Ruth Wilson
     
    United Kingdom
     
    Head of Group Corporate Governance
    Daniel Wang Kit Wong
     
    United Kingdom
     
    Head of Corporate Treasury
    Ridirectors Limited (Globe House, 1 Water Street,
    London, England, WC2R 3LA)
     
    Incorporated in the United Kingdom
     
    Corporate director (non-trading company)

    Weston (2009) Limited

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Jerome Abelman
     
    U.S.A
     
    Director, Legal and External Affairs and General Counsel
    Tadeu Marroco
     
    Brazil
     
    Finance and Transformation Director



    B.A.T. Industries p.l.c.

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Andrew James Barrett
     
    United Kingdom
     
    Group Financial Controller and Head of M&A
    Steven Dale
     
    United Kingdom
     
    Group Head of Corporate Tax
    Paul McCrory
     
    United Kingdom
     
    Assistant General Counsel – Corporate Legal & Group Company Secretary
    Neil Arthur Wadey
     
    United Kingdom
     
    Group Treasurer

    British-American Tobacco (Holdings) Limited

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Jerome Abelman
     
    U.SA
     
    Director, Legal and External Affairs and General Counsel
    Marina Bellini
     
    Italy, Brazil
     
    Director, Digital and Information
    Jack Bowles
     
    France
     
    Chief Executive
    Luciano Comin
     
    Italy, Argentina
     
    Regional Director, Americas and Sub-Saharan Africa
    Mihovil James Dijanosic
     
    Australia
     
    Regional Director, Asia-Pacific and Middle East
    Zafar Khan
     
    Pakistan
     
    Director, Operations
    Hae In Kim
     
    South Korea
     
    Director, Talent, Culture and Inclusion
    Paul Lageweg
     
    Netherlands
     
    Director, New Categories
    Tadeu Marroco
     
    Brazil
     
    Finance and Transformation Director
    Guy Meldrum
     
    New Zealand
     
    President and CEO, Reynolds American Inc.
    David O’Reilly
     
    United Kingdom
     
    Director, Scientific Research
    Johan Vandermeulen
     
    Belgium
     
    Regional Director, Europe and North Africa
    Kingsley Wheaton
     
    United Kingdom
     
    Chief Marketing Officer

    Louisville Securities Limited

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Andrew James Barrett
     
    United Kingdom
     
    Group Financial Controller and Head of M&A
    Steve Dale
     
    United Kingdom
     
    Group Head of Corporate Tax
    Neil Arthur Wadey
     
    United Kingdom
     
    Group Treasurer
    Ruth Wilson
     
    United Kingdom
     
    Head of Group Corporate Governance
    Anthony Cohn
      United Kingdom  
    Head of Corporate Tax – UK
    Ridirectors Limited (Globe House, 1 Water Street,
    London, England, WC2R 3LA)
     
    Incorporated in the United Kingdom
     
    Corporate director (non-trading company)



    BATUS Holdings Inc.

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    Alden H. Smith (Vice President and Director)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Managing Counsel – Corporate of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Lisa M. Oakes (Secretary and Director)
    4250 Lancaster Pike, Suite 302,
    Wilmington, DE 19805
     
    U.S.A.
     
    Vice President of Corporation Service Company, whose business address is 4250 Lancaster Pike, Suite 302, Wilmington, DE 19805, and whose principal business is the provision of corporate and administrative services.
    Timothy J. Hazlett (President and Director) 627 Eagle Watch Lane,
    Osprey, FL 34229
     
    U.S.A.
     
    Managing Member of T. J. Hazlett, LLC, whose business address is 627 Eagle Watch Lane, Osprey, FL 34229, and whose principal business is the provision of consulting services.
    John R. Whitener (Director)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Senior Vice President of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Nancy G. Sturgeon (Vice President Tax)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Senior Vice President – Tax and Assistant General Counsel of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Caroline M. Price (Treasurer)
    301 North Market Street, Suite 1402 Wilmington, Delaware 19801
     
    U.S.A.
     
    President and Senior Manager Investments of Reynolds Finance Company, whose principal business address is 301 North Market Street, Suite 1402, Wilmington, Delaware 19801
    Patrick Z. Messick (Assistant Secretary)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Senior Director Income Tax of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    James J. Murphy (Vice President)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    United Kingdom and Republic of Ireland
     
    Executive Vice President R&D and Scientific and Regulatory Affairs of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Valerie B. Solomon (Vice President)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Vice President and Assistant General Counsel – Regulatory of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    BT DE Investments Inc.

    Name (and business address where not Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom)
     
    Country of Citizenship
     
    Current Principal Occupation or Employment (and business address and principal business of any corporation or other organization other than a BAT Entity)
    James J. Murphy (President and Director)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    United Kingdom and Republic of Ireland
     
    Executive Vice President R&D and Scientific and Regulatory Affairs of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    John R. Whitener (Treasurer and Director) 401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Senior Vice President of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Matthew R. Triplett (Secretary)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Managing Counsel – Commercial/Corporate of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Patrick Z. Messick (Assistant Secretary)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Senior Director Income Tax of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101
    Valerie B. Solomon (Director)
    401 North Main Street,
    Winston-Salem, NC 27101
     
    U.S.A.
     
    Vice President and Assistant General Counsel – Regulatory of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101



    Get the next $OGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGI

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global's Collective Project Wins Big at the 2025 High Spirits Awards in California

      Wins gold medal for Blood Orange, Yuzu & Vanilla and platinum medal for Mango, Pineapple & Coconut Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce that its recently acquired business, Collective Project, has won recognition at the 2025 High Spirits Awards only a few short months following the launch of the brand in the U.S. The brand received a gold award for Blood Orange, Yuzu & Vanilla and a platinum award for Mango, Pineapple & Coconut hemp-derived THC beverages. High Spirits Awards is a competition launched by L.A. Spirits Awards in 2023 to identify and reward excellence among the growi

      5/7/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export Awards

      Award recognizes exceptional export growth, product innovation, and global market leadership Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), ("the Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce it has been named Exporter of the Year by Opportunities New Brunswick ("ONB") as part of the 2025 New Brunswick Export Awards, ONB's flagship annual event recognizing the successes and innovative approaches of New Brunswick's many exporting companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505021217/en/ This honour recognizes Organigram's significant growth in international cannab

      5/5/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      12/10/24 7:10:15 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      9/3/24 9:30:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      1/25/24 5:23:26 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    SEC Filings

    See more
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/12/25 7:39:04 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/7/25 9:38:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/5/25 11:48:28 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Leadership Updates

    Live Leadership Updates

    See more
    • Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

      3/24/25 8:30:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Craig Harris to Board of Directors

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

      7/29/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Karina Gehring to Board of Directors

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi

      1/19/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Financials

    Live finance-specific insights

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025

        Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2025 ended March 31, 2025, on Monday, May 12, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Monday, May 12, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766371 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a co

      5/2/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Enters U.S. Through Acquisition of Collective Project Beverages

      Acquisition Marks Commercial Market Entry in the Fast-Growing Hemp-Derived THC Beverage Category in the U.S. and the Emerging Canadian Cannabis Beverage Category Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited ("CPL") for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026. This press release features multimedia. View the full

      4/1/25 7:47:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on OrganiGram

      Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

      7/17/24 12:18:49 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Alliance Global Partners

      Alliance Global Partners upgraded OrganiGram from Neutral to Buy

      4/15/24 8:40:01 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Stifel

      Stifel upgraded OrganiGram from Hold to Buy

      1/13/23 7:36:46 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care